Expression of interleukin-16 by human epithelial cells. Inhibition by dexamethasone

Am J Respir Cell Mol Biol. 1999 Dec;21(6):684-92. doi: 10.1165/ajrcmb.21.6.3671.

Abstract

Production of chemoattractants by bronchial epithelial cells may contribute to the local accumulation of inflammatory cells in patients with bronchial asthma and other pulmonary diseases. Recently, interleukin (IL)-16 (lymphocyte chemoattractant factor) was reported to be a potent chemotactic stimulus for CD4(+) T lymphocytes and eosinophils, the types of leukocyte found in the proximity of bronchial epithelium in asthmatic individuals. To test the possibility that bronchial epithelial cells produce IL-16, we analyzed RNA and culture supernatants from the human bronchial epithelial cell line BEAS-2B, using reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. BEAS-2B constitutively expressed IL-16 messenger RNA (mRNA) and protein; IL-16 expression was significantly upregulated in a concentration-dependent manner within 24 h by stimulation with histamine, IL-1beta, or tumor necrosis factor (TNF)-alpha whereas interferon-gamma did not significantly increase IL-16. Findings in BEAS-2B cells were confirmed in primary bronchial epithelial cells. Using TA cloning, IL-16 was cloned from BEAS-2B airway epithelial cells. Sequence analysis confirmed its near identity with lymphocyte-derived IL-16. The combination of IL-1beta and TNF-alpha had an additive effect on IL-16 expression. This combination of cytokines also had a priming effect on histamine-induced IL-16 mRNA expression, which was observed within 24 h and which increased to at least 48 h after stimulation. The IL-16 expression induced by histamine and combined cytokines was significantly inhibited by pretreatment with the protein synthesis inhibitor cycloheximide (10 microg/ml). Pretreatment with dexamethasone also significantly suppressed the expression of IL-16, in a concentration-dependent manner. Sputum samples from asthmatic subjects were found to have higher levels of IL-16 than were samples from subjects with other pulmonary inflammatory diseases. These findings suggest that bronchial epithelial cells have the capacity to produce IL-16 after stimulation with histamine, IL-1beta, and TNF-alpha, and raise the possibility that epithelium-derived IL-16 may play a role in recruitment of eosinophils and CD4(+) T lymphocytes in the airways. Downregulation of IL-16 expression by dexamethasone suggests that glucocorticoids may inhibit airway inflammation partly by suppressing the synthesis of inflammatory cytokines including IL-16.

MeSH terms

  • Adult
  • Aged
  • Asthma / immunology
  • Bronchi
  • Bronchiectasis / immunology
  • Bronchiolitis / immunology
  • Cell Line
  • Cycloheximide / pharmacology
  • Dactinomycin / pharmacology
  • Dexamethasone / pharmacology*
  • Down-Regulation
  • Epithelial Cells / drug effects*
  • Epithelial Cells / metabolism
  • Female
  • Gene Expression Regulation / drug effects
  • Histamine / pharmacology
  • Humans
  • Interleukin-1 / pharmacology
  • Interleukin-16 / genetics
  • Interleukin-16 / metabolism*
  • Male
  • Middle Aged
  • RNA, Messenger / drug effects
  • RNA, Messenger / metabolism
  • Sputum / immunology
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Interleukin-1
  • Interleukin-16
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Dactinomycin
  • Dexamethasone
  • Histamine
  • Cycloheximide